Bangalore, India 9/21/16—Publicly held CRO Syngene International has acquired certain assets from Strand Life Sciences for an undisclosed amount. The assets consist of those related to systems biology, the Heptox Virtual Liver model and pharmaceutical bioinformatics services, including the the target dossier business, and rights to the NGS data analytics and Sarchitect platforms. “Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities,” stated Syngene CEO Jonathan Hunt. “We believe Strand’s bioinformatics platforms not only complement our existing integrated service platforms but will also meet our customers growing needs for bioinformatics and data analytic support.”

Strand Life Sciences’ broad offerings include bioinformatics solutions, drug discovery services and diagnostic tests. Of the acquired business, non-service businesses include the NGS platform for data management, analysis and visualization. Strand has retained its GeneSpring microarray data analysis platform, which is marketed by Agilent and build on Strand’s Avadis data mining and visualization platform.